// App-Quantinova.ai

382 : Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309

Researchers

Presenter

  • Karin Jorga

Principal Investigators

  • Eva Huehn

  • Grace Fraczkiewicz

  • Debora Schmitz

  • Doriano Fabbro

  • Sasa Dimitrijevic

Medical Centers

  • KarinJorga GmbH, Basel, Switzerland

  • SimulationsPlus Inc, Lancaster, CA

  • Piqur Therapeutics AG, Basel, Switzerland

Locations

  • United States

  • Switzerland

Companies

  • Karin Jorga Life Sci

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Solid malignancies

  • Renal artery stenosis

Biomarkers

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • PQR309

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved